Despite a lack of randomized data, hepatic resection or radiofrequency ablation (RFA) has been used for the treatment of colorectal liver metastases (CLM). To evaluate the efficacy of local therapy, the European Intergroup initiated a randomized phase III trial (European Organization for Research and Treatment of Cancer [EORTC] 40004, Chemotherapy + Local Ablation Versus Chemotherapy, CLOCC trial) that assigned patients with unresectable, liver-only metastases from colorectal cancer to systemic treatment alone or systemic treatment plus RFA ± resection (1). The trial was amended to a phase II trial because of slow accrual, and long-term results by Ruers etal. (2) are presented in this issue of the Journal. After follow-up of nearly 10 years, RFA was associated with a statistically significant improvement in five-year overall survival (43.1% vs 30.3%, hazard...

中文翻译：

---

社论：结直肠肝转移的局部治疗：建立当今的证据水平并确定明天的路线图

尽管缺乏随机数据，但肝切除或射频消融（RFA）已用于治疗结直肠肝转移（CLM）。为了评估局部疗法的疗效，欧洲小组发起了一项随机III期试验（欧洲癌症研究与治疗组织[EORTC] 40004，化学疗法+局部消融对化学疗法，CLOCC试验），该研究为患者分配了不可切除的仅肝从大肠癌转移到单独全身治疗或全身治疗加RFA±切除术（1）。由于Ruers等人的缓慢累积和长期结果，该试验被修改为II期试验。（2）在本期杂志上介绍。经过近10年的随访，RFA与5年总生存期的统计显着改善相关（43.1％vs 30）。